Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹75 Cr
verification pending
Revenue YoY
9.8%
reported change
EBITDA
₹15 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Amanta Healthcare reported Q3 FY26 revenue of ₹75 crore (+9.8% YoY) and EBITDA of ₹15 crore (21% margin), with PAT of ₹5 crore (+8.1% YoY). Growth was driven by steady demand in its Sterport IV fluid containers (40% of revenue) and high-margin SVP exports (20% of revenue). Management guided for ₹400 crore revenue in FY27, driven by a doubling of Sterport capacity to ~12 crore bottles (₹120 crore incremental revenue) and a new SVP line (₹30 crore incremental). A 10.8 MW solar plant (commissioning Q1 FY27) is expected to save ₹9 crore annually. Risks include ramp-up delays in SVP exports due to regulatory approvals and potential working capital strain from inventory buildup during capacity commissioning.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects revenue to reach ~₹400 crore in FY27, driven by Sterport capacity doubling and SVP expansion, implying ~33% YoY growth.
- The new Sterport line is expected to generate incremental revenue of ₹120 crore (plus/minus 4-5%) once fully ramped.
- Post Sterport capacity commissioning, overall company EBITDA margin is expected to expand by 3-4 percentage points to ~26-27%.
- Management plans to repay ₹35-40 crore of debt annually from cash flows, reducing total debt from ~₹190 crore to ~₹150 crore by FY27 end.
Risks flagged
- SVP expansion targets inhalation solutions for export, but shape variation approvals can take 6-18 months, delaying revenue contribution.
- During Sterport ramp-up, inventory will accumulate for 3-5 months before sales catch up, potentially increasing working capital requirements.
- Competitors like Otsuka and Fresenius may convert existing lines to two-port systems, increasing supply and pressuring pricing.
- Management acknowledged that strengthening middle management and product development spending has temporarily pressured EBITDA margins.
Key quotes
- We must have sold more than 35 cr bottles so far. We have not got a single complaint of fungal contamination.
- Incremental capacity will produce much higher EBITDA levels... post commissioning company's overall EBITDA will expand by 3 to 4%.
- Next year we'll see sizable increase... we are hoping to be in the range of roughly 400 cr.
Research modules